LENZ
LENZ Therapeutics, Inc.Company Information
- Company Name
- LENZ Therapeutics, Inc.
- CIK
- CIK0001815776
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- LENZ: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- LENZ
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-27
- Last sale
- 2025-11-17
- Shares purchased (TTM)
- 53,879
- Shares sold (TTM)
- 1,186,969
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 33,927,239
- Shares outstanding
- 31,374,311
- Ownership
- 108.14%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 14.40%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | - | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | 54 | 54 | - | ||||||
Assets | ||||||||||||||||||
| Assets Held For Sale Long Lived Fair Value Disclosure | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Series A1 Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Series B Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 24 | 25 | 25 | 25 | 38 | 23 | 20 | 41 | 84 | 200 | 35 | 183 | ||||||
| Restricted Cash Equivalents | - | - | - | - | - | - | - | - | - | - | 2 | - | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | 176 | 112 | 13 | 0 | 51 | ||||||
| Class B Convertible Common Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Current | 196 | 234 | 267 | 177 | 172 | 171 | 189 | - | - | - | 31 | - | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Inventory Net | 4 | 3 | 3 | 1 | - | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 9 | 6 | 6 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 1 | 5 | ||||||
| Restricted Cash Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Restricted Cash Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 2 | ||||||
| Assets Current | 233 | 268 | 301 | 207 | 214 | 198 | 212 | 221 | 199 | 217 | 67 | 239 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 13 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 0 | 13 | ||||||
| Other Assets Noncurrent | 2 | 2 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | - | 0 | 0 | ||||||
| Assets | 237 | 273 | 306 | 211 | 217 | 201 | 215 | 224 | 203 | 217 | 70 | 266 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Deferred Costs | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 3 | - | ||||||
| Deposits Assets Noncurrent | - | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Employee Related Liabilities Current | - | - | - | - | - | - | - | - | - | - | 2 | 2 | ||||||
| Accounts Payable Current | 7 | 11 | 4 | 4 | 3 | 4 | 4 | 3 | 4 | 7 | 6 | 4 | ||||||
| Accrued Liabilities Current | 10 | 15 | 17 | 12 | 8 | 5 | 6 | 5 | 4 | 12 | 13 | - | ||||||
| Contract With Customer Liability Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 17 | 26 | 21 | 16 | 10 | 9 | 10 | 8 | 9 | 19 | 19 | 13 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 50 | ||||||
| Other Liabilities | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 3 | ||||||
| Liabilities | 17 | 26 | 22 | 17 | 11 | 9 | 11 | 9 | 10 | 19 | 20 | 62 | ||||||
Stockholders Equity | ||||||||||||||||||
| Other Liabilities Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Value | 0 | 0 | 0 | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 520 | 516 | 511 | 385 | 381 | 352 | 349 | 347 | 315 | 310 | 3 | 548 | ||||||
| Retained Earnings Accumulated Deficit | -301 | -269 | -227 | -191 | -175 | -160 | -145 | -132 | -122 | -112 | -95 | -344 | ||||||
Temporary Equity | ||||||||||||||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Stockholders Equity | 219 | 246 | 284 | 194 | 206 | 192 | 204 | 215 | 193 | 198 | -93 | -70 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 143 | - | ||||||
| Liabilities And Stockholders Equity | 237 | 273 | 306 | 211 | 217 | 201 | 215 | 224 | 203 | 217 | 70 | 266 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | - | - | - | 10 | - | - | - | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 16 | 300 | ||||||
| Common Stock Shares Issued | 31 | 31 | 31 | 29 | 29 | 28 | 28 | 28 | 26 | 26 | 2 | 58 | ||||||
| Shares Outstanding | 31 | 31 | 31 | 29 | 29 | 28 | 28 | 27 | 26 | 26 | 2 | 58 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLENZ Therapeutics, Inc. (LENZ) — SEC Financial Statements & Analysis
LENZ Therapeutics, Inc. (LENZ) is a biological products, (no diagnostic substances) company, incorporated in DE. LENZ Therapeutics, Inc. trades on Nasdaq as: LENZ. LENZ Therapeutics, Inc. (LENZ)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, LENZ Therapeutics, Inc. carries a market cap of $178.21M, a P/E ratio of -1.41x, a P/B ratio of 0.81x, a P/S ratio of 8.96x, an enterprise value of $154.00M, and an EV/EBITDA multiple of -1.14x. On profitability, it posts an operating margin of -682.14%, a net margin of -633.59%, a Return on Equity (ROE) of -59.21%, a Return on Assets (ROA) of -55.52%, and a Return on Invested Capital (ROIC) of -74.50%. Per share, it reports EPS of $-4.02, diluted EPS of $-4.02, free cash flow per share of $-3.65, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 297.74% year-over-year, net income growth of 140.47% year-over-year, and EPS growth of 115.21% year-over-year. On the balance sheet, it maintains a current ratio of 13.55x, a quick ratio of 12.81x, working capital of $216.07M, a debt-to-equity ratio of 0.08x, a debt ratio of 0.07, free cash flow of $-114.42M (TTM), and net debt of $-24.21M. Figures sourced from SEC EDGAR.
- Market Cap
- $178.21M
- P/E TTM
- -1.41x
- EPS TTM
- $-4.02
- P/B TTM
- 0.81x
- ROE TTM
- -59.21%
- ROA TTM
- -55.52%
- Debt To Equity
- 0.08x
- Free Cash Flow TTM
- $-114.42M
- Net Revenue TTM Growth 1Y
- 297.74%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is LENZ Therapeutics, Inc. in?
LENZ Therapeutics, Inc. (LENZ) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does LENZ trade on?
LENZ Therapeutics, Inc. (LENZ) trades on the Nasdaq.
Where is LENZ Therapeutics, Inc. incorporated?
LENZ Therapeutics, Inc. is incorporated in DE.
When was LENZ Therapeutics, Inc. (LENZ)'s most recent SEC filing?
LENZ Therapeutics, Inc. (LENZ)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is LENZ's market cap?
LENZ Therapeutics, Inc. (LENZ) has a market capitalization of $178.21M as of 2026-06-30.
What is LENZ's EPS (earnings per share)?
LENZ Therapeutics, Inc. (LENZ)'s trailing twelve month EPS is $-4.02 as of 2026-06-30.
What is LENZ's ROE (return on equity)?
LENZ Therapeutics, Inc. (LENZ)'s trailing twelve month Return on Equity (ROE) is -59.21% as of 2026-06-30.
What is LENZ's ROA (return on assets)?
LENZ Therapeutics, Inc. (LENZ)'s trailing twelve month Return on Assets (ROA) is -55.52% as of 2026-06-30.
What is LENZ's ROIC (return on invested capital)?
LENZ Therapeutics, Inc. (LENZ)'s trailing twelve month Return on Invested Capital (ROIC) is -74.50% as of 2026-06-30.
What is LENZ's EV/EBITDA?
LENZ Therapeutics, Inc. (LENZ)'s trailing twelve month EV/EBITDA is -1.14x as of 2026-06-30.